Current problems in cancer · 2026
Too late to fall: Time to PSA nadir and early oncologic failure after cryotherapy and high-intensity focused ultrasound for localized prostate cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Anceschi Umberto, Basile Salvatore, Misuraca Leonardo, Mastroianni Riccardo, Flammia Rocco Simone, D'Annunzio Simone, Bove Alfredo Maria, Capecchi Riccardo, Proietti Flavia, Prata Francesco, Ferriero Mariaconsiglia, Capecchi Lorenzo, Lugnani Franco, Simone Giuseppe
Аннотация
INTRODUCTION: The ability of time to PSA nadir (TTN) to predict early treatment failure after focal therapy for prostate cancer remains unclear. We assessed whether TTN and PSA nadir-related parameters are associated with early oncologic failure after primary cryotherapy or high-intensity focused ultrasound (HIFU).
MATERIALS AND METHODS: We relied on a prospective registry of 319 men treated with primary cryotherapy (n = 221) or HIFU (n = 98). TTN was categorised as ≤6, 6-12, or >12 months. PSA nadir and nadir PSA density (nPSAD) were analysed. Treatment failure (TF) included biochemical/local recurrence, metastatic progression, or salvage therapy. Primary endpoint was early TF (≤24 months). Independent predictors were evaluated with Firth logistic regression; failure-free survival (FFS) was estimated with Kaplan-Meier analysis.
RESULTS: Men selected for HIFU had slightly more favourable baseline features. Median TTN was 6 months overall but longer after cryotherapy than after HIFU (6 vs 3 months; p < 0.001). Cryotherapy achieved lower PSA nadir and nPSAD than HIFU (each p < 0.001). At a median follow-up of 26 months, overall FFS was 84.8% (82.1% after cryotherapy and 90.8% after HIFU; p = 0.046). TTN strata were associated with differences in FFS (log-rank p < 0.001). In multivariable models, TTN >12 months independently predicted early TF after cryotherapy (OR 17.5; p < 0.001). After HIFU, ablation extent was independently associated with early treatment failure.
CONCLUSIONS: Delayed TTN was independently associated with early failure after cryotherapy, whereas no independent association emerged after HIFU. These findings support modality-specific interpretation of TTN when planning post-ablation follow-up.
MATERIALS AND METHODS: We relied on a prospective registry of 319 men treated with primary cryotherapy (n = 221) or HIFU (n = 98). TTN was categorised as ≤6, 6-12, or >12 months. PSA nadir and nadir PSA density (nPSAD) were analysed. Treatment failure (TF) included biochemical/local recurrence, metastatic progression, or salvage therapy. Primary endpoint was early TF (≤24 months). Independent predictors were evaluated with Firth logistic regression; failure-free survival (FFS) was estimated with Kaplan-Meier analysis.
RESULTS: Men selected for HIFU had slightly more favourable baseline features. Median TTN was 6 months overall but longer after cryotherapy than after HIFU (6 vs 3 months; p < 0.001). Cryotherapy achieved lower PSA nadir and nPSAD than HIFU (each p < 0.001). At a median follow-up of 26 months, overall FFS was 84.8% (82.1% after cryotherapy and 90.8% after HIFU; p = 0.046). TTN strata were associated with differences in FFS (log-rank p < 0.001). In multivariable models, TTN >12 months independently predicted early TF after cryotherapy (OR 17.5; p < 0.001). After HIFU, ablation extent was independently associated with early treatment failure.
CONCLUSIONS: Delayed TTN was independently associated with early failure after cryotherapy, whereas no independent association emerged after HIFU. These findings support modality-specific interpretation of TTN when planning post-ablation follow-up.